AEZS - Aeterna Zentaris Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5300
-0.0800 (-4.9689%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close1.6100
Open1.6200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.5300 - 1.6700
52 Week Range0.7800 - 3.7500
Volume109,974
Avg. Volume140,501
Market Cap24.427M
Beta1.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press28 days ago

    Aeterna Zentaris reports 4Q loss

    On a per-share basis, the Montreal-based company said it had a loss of 3 cents. Losses, adjusted for pretax gains, came to 24 cents per share. The drug developer posted revenue of $178,000 in the period. ...

  • March Best Growth Stocks
    Simply Wall St.last month

    March Best Growth Stocks

    Companies such as Emblem and Aeterna Zentaris have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio should consider theseRead More...

  • Top TSX Growth Stocks To Buy
    Simply Wall St.2 months ago

    Top TSX Growth Stocks To Buy

    Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Knight Therapeutics and Callidus Capital are deemed to be superiorRead More...

  • 5 Great Breakout Stocks Offering Superlative Returns
    InvestorPlace3 months ago

    5 Great Breakout Stocks Offering Superlative Returns

    In order to select the right breakout stock one has to first calculate its support and resistance level. A support level is the lower bound for stock movements while a resistance level refers to the maximum price which it trades within over a considerable period. In other words, the demand for a stock is at its lowest at its support level, which means most traders are willing to sell it.

  • Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
    Zacks3 months ago

    Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service

    Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service

  • 5 Great Breakout Stocks Offering Superlative Returns
    Zacks3 months ago

    5 Great Breakout Stocks Offering Superlative Returns

    This method involved zeroing in on those stocks whose prices are varying within a narrow band.

  • Market Exclusive3 months ago

    Here’s What’s Moving Novartis And Aeterna Zentaris Right Now

    Novartis (NYSE: NVS) and Aeterna Zentaris Inc. (NASDAQ: AEZS) both saw spikes in volume and subsequent share price movement in the biotechnology and healthcare markets during the middle of this week. Here’s what happened with each and what comes next. Novartis This biotechnology behemoth reported on Wednesday that the US Food and Drug Administration (FDA) […] The post Here’s What’s Moving Novartis And Aeterna Zentaris Right Now appeared first on Market Exclusive.

  • AEterna Zentaris Inc. (USA) (AEZS) Stock Fires Up to the Roof; Here’s Why
    SmarterAnalyst3 months ago

    AEterna Zentaris Inc. (USA) (AEZS) Stock Fires Up to the Roof; Here’s Why

    AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) investors are busy throwing a party today following the news that tiny drug maker has sold its U.S. and Canadian rights to MACRILEN™ (macimorelin), a drug designed to evaluate adults for growth hormone deficiency, to Strongbridge Biopharma (NASDAQ:SBBP). Under the terms of the license and assignment agreement, Strongbridge will make an upfront payment of $24 million to Aeterna Zentaris within five days of the effective date of the agreement.  Strongbridge has agreed to pay tiered royalties in the mid-to-high teens as a percentage of net sales as well as milestone payments upon FDA approval of a pediatric indication and the achievement of pre-determined sales levels. The license and assignment agreement also provides Strongbridge with an exclusive license to manufacture and commercialize MACRILEN in the U.S. and Canada.

  • Aeterna Zentaris jumps on FDA approval, Honda bets on solid-state battery, Rolling Stone is sold
    Yahoo Finance4 months ago

    Aeterna Zentaris jumps on FDA approval, Honda bets on solid-state battery, Rolling Stone is sold

    Aeterna Zentaris, Honda, Rolling Stone and Didi Chuxing are the companies to watch.

  • Stocks push slightly higher, President Trump prepares to sign tax bill into law
    Yahoo Finance4 months ago

    Stocks push slightly higher, President Trump prepares to sign tax bill into law

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.

  • Market Exclusive4 months ago

    Here’s How AbbVie (NYSE:ABBV) and Aeterna Zentaris Inc. (NASDAQ:AEZS) Just Picked Up Early Christmas Present

    We are quickly closing in on the end of the week and it’s been a pretty big one in the biotechnology space for a whole host of reasons. The FDA scored a record number of approvals for the year with a trio of unexpected, early green lights and some of the biggest names in the […] The post Here’s How AbbVie (NYSE:ABBV) and Aeterna Zentaris Inc. (NASDAQ:AEZS) Just Picked Up Early Christmas Present appeared first on Market Exclusive.

  • SmarterAnalyst4 months ago

    AEterna Zentaris Inc. (USA) (AEZS) Investors Celebrate FDA Approval; Shares Skyrocket

    Case in point: AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), whose shares are jumping nearly 60% in after-hours trading Wednesday. The drug maker won FDA approval for Macrilen™ (macimorelin), the company's product candidate for the diagnosis of Adult Growth Hormone Deficiency (AGHD). The Company estimates that approximately 60,000 tests for suspected AGHD are being conducted each year across the United States, Canada and Europe.

  • Reuters4 months ago

    Canada's Aeterna gets FDA approval for growth hormone deficiency test

    Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency. The company said it intends to launch the test, Macrilen, in the United States during the first quarter of 2018. Macrilen stimulates the secretion of growth hormone, which is then measured via blood samples.

  • SmarterAnalyst5 months ago

    Ahead of Big Catalyst, AEterna Zentaris Inc. (AEZS) Announced Departure of Interim Chief Financial Officer

    December is an exciting month for AEterna Zentaris Inc. (NASDAQ:AEZS) investors, with the upcoming PDUFA on December 30 for Macrilen (macimorelin), for the evaluation of growth hormone deficiency in adults (AGHD). Ahead of the big catalyst, the tiny drug maker announced today the departure of Jeffrey Whitnell, the Company’s Interim Chief Financial Officer, effective December 7, 2017.  The Company is currently reviewing its resource requirements with respect to its finance department and has commenced a search for Mr. Whitnell's replacement as principal financial officer.

  • Benzinga5 months ago

    Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

    The weakness that surfaced in biotech in October in the wake of disappointing earnings from some companies in the sector extended into November. Notwithstanding the short-term weakness, biotech stocks ...

  • AEterna Zentaris Inc.’s (USA) (AEZS) Growth Hormone Drug Accepted for EU Review
    SmarterAnalyst5 months ago

    AEterna Zentaris Inc.’s (USA) (AEZS) Growth Hormone Drug Accepted for EU Review

    AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that the Marketing Authorization Application (MAA) for the use of Macrilen™ (macimorelin) for the evaluation of adult growth hormone deficiency (AGHD) has been accepted by the European Medicines Agency (EMA) for regulatory review. "Our goal is to relieve the burden of AGHD testing for physicians worldwide and most importantly for patients and the EMA’s acceptance of our MAA brings us closer to achieving that,” said Michael V. Ward, Chief Executive Officer, Aeterna Zentaris.

  • Associated Press5 months ago

    Aeterna Zentaris reports 3Q loss

    On a per-share basis, the Montreal-based company said it had a loss of 61 cents. Losses, adjusted for non-recurring costs, came to 44 cents per share. The drug developer posted revenue of $241,000 in the ...

  • SmarterAnalyst5 months ago

    Company Update: AEterna Zentaris Inc. (AEZS) Announces 3Q:17 Highlights and Financial Results

    AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the third quarter ended September 30, 2017. Company adopts disciplined business model focused on cost containment through zero-based budgeting and preserving cash reserves for Macrilen™ product launch. “We are continuing our laser focus on preparation for the FDA approval of Macrilen™ by December 30, 2017, which will be the only FDA-approved drug for assessing adult growth hormone deficiency in the United States,” said Michael V. Ward, Aeterna Zentaris, Chief Executive Officer.

  • Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube8 months ago

    Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Æterna Zentaris, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Æterna Zentaris, Inc. – Spectrum Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Bristol-Myers Squibb Company, Sanofi Sponsored ADR, Novartis AG Sponsored ADR, Halozyme Therapeutics, Inc. and Theratechnologies Inc. (SPPI-US, KERX-US, ... Read more (Read more...)

  • Associated Press8 months ago

    Aeterna Zentaris reports 2Q loss

    The Montreal-based company said it had a loss of 18 cents per share. Losses, adjusted for non-recurring gains, were 46 cents per share. The drug developer posted revenue of $243,000 in the period. In the ...

  • SmarterAnalyst9 months ago

    AEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions

    AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday's trading session, following the news that CEO David Dodd is stepping down and will be succeed by Michael Ward. Most recently, Ward served as Chief Compliance & Legal Officer and Corporate Secretary for Sagent Pharmaceuticals and led its sale to Nichi-Iko Pharmaceutical for $736 million. If David Dodd turned around AEZS, why is he out?

  • Aeterna Zentaris jumps on FDA approval, Honda bets on solid-state battery, Rolling Stone is sold
    Yahoo Finance Video4 months ago

    Aeterna Zentaris jumps on FDA approval, Honda bets on solid-state battery, Rolling Stone is sold

    Aeterna Zentaris, Honda, Rolling Stone and Didi Chuxing are the companies to watch.

  • Yahoo Finance Live: Market Movers - Dec 21st, 2017
    Yahoo Finance Video4 months ago

    Yahoo Finance Live: Market Movers - Dec 21st, 2017

    Yahoo Finance's LIVE stock market coverage and analysis.